RXRX — Recursion Pharmaceuticals, Inc. - Class A Common Stock
Session close: $2.72. Regular-session share volume: 37,291,779. Change from previous close: -6.37%.
Key developments
J.P. Morgan analyst Priyanka Grover reaffirmed a Buy rating on Recursion Pharmaceuticals with a price target, keeping a constructive stance on the biotechnology company ahead of the session. The note reflects the firm's current outlook on the company's performance and market position rather than any newly disclosed operational development.
Company news J.P. Morgan Maintains Buy Rating for Recursion Pharmaceuticals
News sources
Company news J.P. Morgan Maintains Buy Rating for Recursion Pharmaceuticals